896160-99-9

Basic information

• Product Name: 5-Bromo-N,N-dimethylpyridine-3-sulfonamide
• Synonyms: 5-Bromo-N,N-dimethylpyridine-3-sulfonamide;N,N-Dimethyl 5-bromopyridine-3-sulfonamide
• CAS NO: 896160-99-9
• Molecular Formula: C₇H₉BrN₂O₂S
• Molecular Weight: 265.13
• Mol File: 896160-99-9.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-Bromo-N,N-dimethylpyridine-3-sulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-N,N-dimethylpyridine-3-sulfonamide(896160-99-9)
• EPA Substance Registry System: 5-Bromo-N,N-dimethylpyridine-3-sulfonamide(896160-99-9)

Safety Data

• Hazardous Substances Data: 896160-99-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
5-Bromo-N,N-dimethylpyridine-3-sulfonamide is used as a research compound for exploring its potential as an antifungal or antiparasitic agent due to its unique chemical structure and biological activity.
Used in Organic Synthesis:
In the field of organic synthesis, 5-Bromo-N,N-dimethylpyridine-3-sulfonamide serves as a key intermediate or building block in the creation of more complex molecules, leveraging its reactive functional groups for further chemical transformations.
Used in Drug Development:
5-Bromo-N,N-dimethylpyridine-3-sulfonamide is utilized as a candidate in drug development, where its potential medicinal properties are evaluated and optimized for therapeutic applications, particularly in the treatment of fungal and parasitic infections.
Used in Medicinal Chemistry:
In medicinal chemistry, 5-Bromo-N,N-dimethylpyridine-3-sulfonamide is employed as a template for the design and synthesis of new drugs, taking advantage of its chemical properties to create novel therapeutic agents with improved efficacy and selectivity.
Used in Chemical Biology:
5-Bromo-N,N-dimethylpyridine-3-sulfonamide is applied in chemical biology to study its interactions with biological targets, such as enzymes or receptors, to understand its mode of action and potential as a lead compound for the development of new pharmaceuticals.

Upstream product

• 65001-21-0 5-bromopyridine-3-sulphonyl chloride 
• 124-40-3 dimethyl amine 
• 913836-25-6 5-bromopyridine-3-sulphonyl chloride hydrogen chloride 

Downstream Products

• 1240289-11-5 tert-butyl [4-chloro-2-({5-[(dimethylamino)sulfonyl]pyridin-3-yl}ethynyl)phenoxy]acetate 
• 1383988-48-4 5-(2-amino-4-oxo-3-phenyl-3,4-dihydro-6-quinazolinyl)-N,N-dimethyl-3-pyridinesulfonamide 

Relevant articles and documents

AZA-HETEROARYL COMPOUNDS AS PI3K-GAMMA INHIBITORS

The present invention provides aza-heteroaryl derivatives of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A, W, R4, R5, and R6 are defined herein, that inhibit the activity of phosphoinositide 3-kinases-gamma (PI3Kγ) and are useful in the treatment of diseases related to the activity of PI3Kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

Discovery of potent, selective, and orally bioavailable alkynylphenoxyacetic acid CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases

New phenoxyacetic acid antagonists of CRTH2 are described. Following the discovery of a hit compound by a focused screening, high protein binding was identified as its main weakness. Optimization aimed at reducing serum protein binding led to the identification of several compounds that showed not only excellent affinities for the receptor (41 compounds with Ki 50 100 nM; PGD2-induced eosinophil shape change). Additional optimization of the PK characteristics led to the identification of several compounds suitable for in vivo testing. Of these, 19k and 19s were tested in two different pharmacological models (acute FITC-mediated contact hypersensitivity and ovalbumin-induced eosinophilia models) and found to be active after oral dosing (10 and 30 mg/kg).

PHENOXY ACETIC ACID DERIVATIVES

The present invention provides phenoxyacetic acid derivatives of Formula (I) for the treatment of CRTH2 related disorders and disease selected from asthma, atopic dermatitis and inflammatory dermatoses.